Mr. Andre Larente reports

DIAGNOS ANNOUNCES CLOSING OF PRIVATE PLACEMENT

Diagnos Inc. has closed a non-brokered private placement, initially announced on Sept. 3, 2025, of 10 units issued at a price of $10,000 per unit, for gross proceeds of $100,000.

Each unit consists of:

• One $10,000 unsecured convertible debenture; and
• 10,000 stock warrants.

Each debenture has a term of 12 months ending on Sept. 5, 2026, and bears interest at the annual rate of 10 per cent payable in cash on a semi-annual basis. At the option of the holder of the debenture, the principal amount may be converted, at any time during the term, into common shares of the corporation at a price of 28 cents per share.

Each warrant entitles the holder to purchase one share at a price of 40 cents per share at any time during the term.

The proceeds from the private placement will be used mainly to finance product development and commercialization of artificial-intelligence-based screening services as well as general and administrative expenses. The units have been subscribed by one director of the corporation. The director is considered a related party of the corporation within the meaning of Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions). The transaction is exempt from the valuation requirement and the minority approval requirement prescribed in MI 61-101, based on sections 5.5(a) and 5.7(1)(a), as the fair market value of the related-party participation in the private placement does not exceed 25 per cent of the corporation's market capitalization. The board of directors of the corporation has reviewed and approved the private placement to ensure that it was in the best interest of the corporation and its shareholders. All securities to be issued as part of the private placement are subject to a statutory hold period ending on Jan. 6, 2026. The private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as full receipt of funds and execution of formal documentation. All moneys quoted in this press release shall be stated and paid in lawful money of Canada.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging artificial intelligence, Diagnos aims to provide more information to health care clinicians to enhance diagnostic accuracy, streamline workflows and improve patient outcomes on a global scale.

We seek Safe Harbor.